3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
61
Stomach Neoplasms
10
HER2-positive Breast Cancer
7
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Inflammatory Breast Neoplasms
3
Breast Diseases
3
Brain Neoplasms
3
Pathologic Complete Response
2
Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Cardiotoxicity
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Relapsed Pediatric Solid Tumor
1
Pancreatic Neoplasms
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Invasive Breast Cancer
1
Intestinal Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Gastric Cancer
1
HER2-positive
1
HER2+ Early or Locally Advanced Breast Cancer
1
HER2+ Breast Cancer
1
HER2 Positive Breast Cancer
1
HER-2 Positive Gastric Cancer
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Feasibility
1
Interventions
Amplified Fragment Length Polymorphism Analysis
2
entrectinib
1
Vinorelbine
1
Trastuzumab
1
Radiomics
1
Pharmacogenomic Testing
1
Neoadjuvant Therapy
1
Molecular Diagnostic Techniques
1
Letrozole
1
Goserelin
1
Gene Expression Profiling
1
Epirubicin
1
Docetaxel
1
Cyclophosphamide
1
Capecitabine
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Lobular
×
Trastuzumab
×
Clear all
NCT01641406
2012-07-16
NACprotocol
Auxilio Mutuo Cancer Center
Phase 2
Unknown
60 enrolled